Cisplatin has been used for over 40 years in various cancer chemotherapies. Toxicity induced by cisplatin-based therapeutic regimens include gastrointestinal toxicity, myelotoxicity, neurotoxicity, ototoxicity and nephrotoxicity. Cisplatin-based regimens have been associated with a wide range of cardiovascular complications. In this paper, we report 2 cases of cisplatin-induced cardiotoxicity.
INTrodUCTIoN
Cisplatin has been used for over 40 years in various cancer chemotherapies -it was first identified in 1960s [1, 2, 3] . It is a prototype from platinum group of antineoplastic drugs, which shows cure rates of nearly 90% in testicular cancers [4] . Cisplatin is also used in other cancers, including ovarian, cervical, small cell lung cancer as well as head and neck cancers [5] . The antitumor activity of cisplatin is associated with gastrointestinal toxicity, myelotoxicity, ototoxicity and neurotoxicity [1] , and the chief, dose-limiting toxicity of cisplatin is nephrotoxicity [6] . Cisplatin-based regimens have been associated with a wide range of venous and arterial thromboembolic complications [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Arterial events are relatively less common than venous thromboembolic complications [11] . We report 2 cases of acute myocardial infarction after cisplatin-based chemotherapy.
CAse PreseNTATIoN Case 1
Mrs. X, a 27-year-old female from Bangladesh, presented with the following medical history: 2 months after second trimester abortion, patient underwent a laparotomy and myomectomy for a suspected uterine fibroid. The histopathological diagnosis was dysgerminoma. Baseline imaging showed no distant metastasis. The patient had no coronary risk factors and was scheduled for chemotherapy with two cycles of BEP regimen (bleomycin, etoposide, cisplatin) to be followed by surgery.
On the 8 th day of the second cycle of BEP regimen, the patient presented to the emergency department with complaints of chest pain. She had an epigastric and anterior chest wall pain which was radiating to the jaw, occasional breathlessness on exertion and myalgia for one day. At the time of presentation, the heart rate was 110/min, blood pressure 160/110 mmHg, the chest was clear and the heart sounds were normal. ECG showed 
Case 2
Mr. Y, a 35-year-old male, presented with complaints of cough.
A CT scan of the chest showed an anterior mediastinal mass, with bilateral lung nodules and liver lesions. β-hCG levels were at 1,000,000 mIU/ml. The histopathological diagnosis was choriocarcinoma. The patient had no comorbidities, was a non-addict with no significant family history. Baseline ECG showed sinus tachycardia ( fig. 3 ). The patient was planned for chemotherapy.
In the 
dIsCUssIoN
Over the past few decades, there have been reports of cisplatin-associated cardiovascular toxicity manifested as both acute The first patient reported here had the onset of symptoms on the 8 th day of the 2 nd cycle and the second patient presented with symptoms on the 3 rd day after the 5 th dose of cisplatin. The timing of the MI in relation to the start of the therapy further implies a relation between cisplatin and MI event. Previously reported myocardial infarction cases were observed 9 days after the completion of the 1 st cycle to 18 months after the completion of 6 cycles of treatment [19] . In studies by Lee et al. and
Moore et al., the cumulative dose of cisplatin did not correlate with TEE occurrence [11, 20] . A recent meta-analysis suggested that a bigger dose of cisplatin was associated with a higher risk of thromboembolism [21] .
The mechanism behind the cisplatin-induced cardiovascular events is unclear. However, many hypotheses have been put forward. Several studies proposed that hypomagnesemia caused by cisplatin could lead to enhanced coagulation capacity and damage to vascular endothelial cells. Hypomagnesemia also results in increased intracellular concentration of calcium, ultimately leading to coronary vasospasm [22] [23] [24] . Some studies indicated an increase in von Willebrand factor levels leading to platelet adhesion and initiation of coagulation process in a big number of thromboembolic events [25] . Other factors, including Virchow's triad, have been implicated in the possible mechanisms for myocardial infarction and thromboembolic events [26] . Patients on chemotherapy frequently present with symptoms of retrosternal burning. Regardless of the patient's age, the doctor should carefully watch out for symptoms of ACS when administering cisplatin-based therapy. In both cases presented in the article, these symptoms were promptly detected, which allowed for a timely intervention.
CoNCLUsIoNs
Patients receiving cisplatin-based regimen should be treated with a high degree of caution for cardiovascular events, because early recognition and appropriate treatment will prevent the morbidity and mortality associated with permanent damage. Many patients receiving BEP are young and usually do not have cardiovascular risk factors, so it may not be appropriate to advocate routine pretreatment cardiac stress test. However, patients with known coronary risk factors must be evaluated and optimized.
